Stocks · News reference
Actinium Pharmaceuticals (AMEX:ATNM) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $(0.21) by 523.81 percent. This is a 504.55 percent increase over losses of $(0.22) per
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development Colorectal cancer data
Filed: 2026-10-15 AccNo: 0001213900-26-109884 Size: 224 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) Evaluation of
Dr. David brings more than two decades of experience across biopharmaceutical operating leadership, healthcare investment banking and equity research. He joins Actinium from CorMedix Inc. (NASDAQ:CRMD), where he most